Instil Bio, Inc. Interest Expense
Instil Bio, Inc. (TIL) reported Interest Expense of $1.98 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-10.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-10
- Instil Bio, Inc. interest expense for the quarter ending 2024-03-31 was $1.98M, a 211.48% increase year-over-year.
- Instil Bio, Inc. interest expense for the quarter ending 2023-12-31 was $1.98M, a 165.77% increase year-over-year.
- Instil Bio, Inc. interest expense for the quarter ending 2023-09-30 was $2.00M, a 148.20% increase year-over-year.
- Instil Bio, Inc. interest expense for the quarter ending 2023-06-30 was $590.00K, a 78.25% increase year-over-year.
- Instil Bio, Inc. interest expense for fiscal 2023 was $5.21M, a 176.63% increase from fiscal 2022.
- Instil Bio, Inc. interest expense for fiscal 2022 was $1.88M.
- Instil Bio, Inc. interest expense for fiscal 2021 was $0.00.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $1.98M 10-Q · filed 2024-05-10 | $3.96M derived: sum of 2 quarters · filed 2024-05-10 | $5.96M derived: sum of 3 quarters · filed 2024-05-10 | $6.55M derived: sum of 4 quarters · filed 2024-05-10 |
| 2023-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $3.98M derived: sum of 2 quarters · filed 2024-03-21 | $4.57M derived: sum of 3 quarters · filed 2024-03-21 | $5.21M 10-K · filed 2024-03-21 |
| 2023-09-30 | $2.00M 10-Q · filed 2023-11-13 | $2.59M derived: sum of 2 quarters · filed 2023-11-13 | $3.23M 10-Q · filed 2023-11-13 | $3.97M derived: sum of 4 quarters · filed 2024-05-10 |
| 2023-06-30 | $590.00K 10-Q · filed 2023-08-14 | $1.23M 10-Q · filed 2023-08-14 | $1.97M derived: sum of 3 quarters · filed 2024-05-10 | $2.78M derived: sum of 4 quarters · filed 2024-05-10 |
| 2023-03-31 | $636.00K 10-Q · filed 2024-05-10 | $1.38M derived: sum of 2 quarters · filed 2024-05-10 | $2.19M derived: sum of 3 quarters · filed 2024-05-10 | $2.52M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $745.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.55M derived: sum of 2 quarters · filed 2024-03-21 | $1.88M derived: sum of 3 quarters · filed 2024-03-21 | $1.88M 10-K · filed 2024-03-21 |
| 2022-09-30 | $807.00K 10-Q · filed 2023-11-13 | $1.14M derived: sum of 2 quarters · filed 2023-11-13 | $1.14M 10-Q · filed 2023-11-13 | $1.14M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $331.00K 10-Q · filed 2023-08-14 | $331.00K 10-Q · filed 2023-08-14 | $331.00K derived: sum of 3 quarters · filed 2023-08-14 | $331.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-05-11 | $0.00 derived: sum of 3 quarters · filed 2023-05-11 | $0.00 derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-12 | $0.00 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |